{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:12Z","timestamp":1761059352729},"reference-count":0,"publisher":"American Society for Microbiology","issue":"11","license":[{"start":{"date-parts":[[1992,11,1]],"date-time":"1992-11-01T00:00:00Z","timestamp":720576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1992,11]]},"abstract":"<jats:p>Oral doses of 400 mg of lomefloxacin were administered once daily prior to breakfast to 10 middle-aged to elderly hospitalized patients with chronic obstructive pulmonary disease during treatment for bronchopulmonary infections. Serial plasma and sputum samples and fractional urine samples were obtained over a steady-state dosing interval. Lomefloxacin concentrations were determined in duplicate by a validated agar well diffusion microbiological assay. The maximum plasma lomefloxacin concentration (4.5 +\/- 1.8 mg\/liter), the time of occurrence of the maximum concentration (1.7 +\/- 1.6 h), and the apparent volume of distribution associated with the terminal phase (2.19 +\/- 1.05 liter\/kg) were comparable to the values reported for healthy, young volunteers. Compared with the data reported for young adults, the elimination half-life (12.7 +\/- 4.67 h) was longer and the apparent total body clearance (132 +\/- 36.6 ml\/min\/1.73 m2) was lower in middle-aged to elderly patients. These differences were most likely attributable to age-related decreases in renal function, as evidenced by the lower lomefloxacin renal clearance (70.3 +\/- 33.5 ml\/min) in patients. The presence of acute respiratory infection per se did not appear to alter lomefloxacin pharmacokinetics. The peak lomefloxacin concentration in purulent, expectorated sputum samples of 4.3 +\/- 1.2 mg\/liter occurred 3.1 +\/- 1.7 h after dose administration and subsequently declined to 1.7 +\/- 0.5 mg\/liter at the end of the 24-h dosing interval. The percent penetration into sputum, as assessed by comparing the area under the curve for sputum and plasma samples, was 120 +\/- 39.8 (range, 70 to 185). The steady-state lomefloxacin concentrations in plasma and sputum samples from ill, older patients were in excess of the MICs for 90% of the strains tested of common, susceptible respiratory pathogens over most of the dosing interval.<\/jats:p>","DOI":"10.1128\/aac.36.11.2458","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T00:05:50Z","timestamp":1340841950000},"page":"2458-2461","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections"],"prefix":"10.1128","volume":"36","author":[{"given":"J M","family":"Kovarik","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University Hospital, Utrecht, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A I","family":"Hoepelman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital, Utrecht, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital, Utrecht, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P A","family":"Sips","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital, Utrecht, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Rozenberg-Arska","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital, Utrecht, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J H","family":"Glerum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital, Utrecht, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Verhoef","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital, Utrecht, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.36.11.2458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.36.11.2458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:26:11Z","timestamp":1645457171000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.36.11.2458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,11]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[1992,11]]}},"alternative-id":["10.1128\/AAC.36.11.2458"],"URL":"https:\/\/doi.org\/10.1128\/aac.36.11.2458","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,11]]},"assertion":[{"value":"1992-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}